A GROUPWIDE PILOT STUDY TO TEST THE TOLERABILITY AND BIOLOGIC ACTIVITY OF THE ADDITION OF AZACITIDINE (IND# 133688, NSC# 102816) TO CHEMOTHERAPY IN INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND KMT2A (MLL) GENE REARRANGEMENT

Registry ID

AALL15P1

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

CHILDRENS ONCOLOGY GROUP

Start date

2019-07-15

Completion date

2025-02-12

Last update

2017-05-05

Conditions

• LYMPHOBLASTIC LEUKEMIA

Related clinical trials

• A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ADMINISTRATION OF SUBCUTANEOUS BLINATUMOMAB FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B ALL
• A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322)
• A PHASE 3 TRIAL INVESTIGATING BLINATUMOMAB (IND #117467, NSC #765986) IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED STANDARD RISK OR DOWN SYNDROME B-LYMPHOBLASTIC LEUKEMIA (B-ALL) AND THE TREATMENT OF PATIENTS WITH LOCALIZED B-LYMPHOBLASTIC LYMPHOMA (B-LLY)
• TOTAL THERAPY FOR INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
• LONG TERM FOLLOW-UP OF PATIENTS EXPOSED TO LENTIVIRAL-BASED CD19 DIRECTED CAR T-CELL THERAPY
• RISK-STRATIFIED RANDOMIZED PHASE III TESTING OF BLINATUMOMAB IN FIRST RELAPSE OF CHILDHOOD B-LYMPHOBLASTIC LEUKEMIA (B-ALL)

View on source registry